Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 801–900 of 1,003
Goñi, F., Martá-Ariza, M., Herline, K., Peyser, D. K., Boutajangout, A., Mehta, P. D., Drummond, E., Prelli, F., & Wısnıewskı, T. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0337-3 · Cited by 21
Green Tea Extracts Attenuate Brain Dysfunction in High-Fat-Diet-Fed SAMP8 Mice
Onishi, S., Meguro, S., Pervin, M., Kitazawa, H., Yoto, A., Ishino, M., Shimba, Y., Mochizuki, Y., Miura, S., Tokimitsu, I., et al. (2019) · Nutrients · doi:10.3390/nu11040821 · Cited by 24
“No effective drugs are currently available on the market for the prevention or early intervention for dementia [55].”
BackgroundFuture horizons in Alzheimer's disease research
Wısnıewskı, T., & Drummond, E. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.08.001 · Cited by 22
Nature’s Derivative(s) as Alternative Anti-Alzheimer’s Disease Treatments
Sharma, A., & Kumar, Y. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190137 · Cited by 22
“For patients with moderate to severe AD, memantine, a N-methyl D-aspartate (NMDA) antagonist, is used [19].”
BackgroundFluorinated Molecules and Nanotechnology: Future ‘Avengers’ against the Alzheimer’s Disease?
Dabur, M., Loureiro, J. A., & Pereira, M. D. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082989 · Cited by 21
“Since then, only four cholinesterase inhibitors and memantine have been marketed for the delay of AD [12].”
BackgroundAMBAR, an Encouraging Alzheimer's Trial That Raises Questions
Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 22
Chan, J., Leung, D. K. Y., Walton, H., Wong, G. H. Y., & Spector, A. E. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1810571 · Cited by 23
“However, due to the intrinsic difficulties in dementia drug research [3], finding a cure remains an ambitious goal, and we must take into consideration the possibility that most people with dementia would not live long enough to benefit from the development of an eventual cure.”
BackgroundYu, J., Cho, E., Kwon, H., Jeon, J., Sin, J. S., Park, J. K., Kim, J., Choi, J. W., Park, S. J., Jun, M., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114366 · Cited by 22
Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias
Yu, L., Boyle, P. A., Wingo, A. P., Yang, J., Wang, T., Buchman, A. S., Wingo, T. S., Seyfried, N. T., Levey, A. I., Jager, P. L. D., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013252 · Cited by 21
“Historically, Alzheimer disease (AD) trials for diseasemodifying agents, including the most recent Food and Drug Administration–approved drug aducanumab, have been directed predominantly against β-amyloid protein and to a lesser extent tau protein.(4) However, the success rates of these trials are disappointingly low.”
BackgroundFan, K., Seah, B., Lu, Z., Wang, T., & Zhou, Y. (2024) · Aging & Mental Health · doi:10.1080/13607863.2024.2358079 · Cited by 22
“The lack of success in drug trials for Alzheimer’s disease (AD) treat-ment has shifted clinicians’ focus toward delaying the progression of MCI to dementia, which could significantly reduce the prevalence and costs of dementia (Cummings et al., 2014; Schneider et al., 2014).”
Zhang, Y.-M., & Wang, G. (2024) · Food & medicine homology. · doi:10.26599/fmh.2025.9420039 · Cited by 20
Calcium Signalling in Neurological Disorders, with Insights from Miniature Fluorescence Microscopy
Sun, D., Amiri, M., Meng, Q., Unnithan, R. R., & French, C. R. (2024) · Cells · doi:10.3390/cells14010004 · Cited by 21
“However, none of the current therapeutic strategies targeting A β plaques have been successful in preventing AD pathogenesis despite providing varying levels of plaque removal [74,75].”
Chang, C.-F., Liou, Y., Lin, T., Ma, S., Hu, Y.-R., Chen, H., & Jong, G. (2019) · Medicine · doi:10.1097/md.0000000000016931 · Cited by 21
Predicting the Potency of Anti-Alzheimer’s Drug Combinations Using Machine Learning
Anastasio, T. J. (2021) · Processes · doi:10.3390/pr9020264 · Cited by 19
JM-20 treatment prevents neuronal damage and memory impairment induced by aluminum chloride in rats
Wong-Guerra, M., Montano-Peguero, Y., Ramírez-Sánchez, J., Jiménez-Martín, J., Fonseca-Fonseca, L. A., Hernández-Enseñat, D., Nonose, Y., Valdés, O., Mondelo-Rodríguez, A., Ortiz-Miranda, Y., et al. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.08.017 · Cited by 23
Qu, C., Zou, Y., Ma, Y., Chen, Q., Luo, J., Fan, H., Jia, Z., Gong, Q., & Chen, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.841696 · Cited by 23
“Developments in disease-modifying therapy for AD have slowly progressed, with a failure rate of 99.6% in clinical trials (Cummings et al., 2014; Marinescu et al., 2019).”
BackgroundInfluentialCoelho, F. C., Cerchiaro, G., Araújo, S. E. S., Daher, J. P. L., Cardoso, S. A., Coelho, G. F., & Guimarães, A. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147935 · Cited by 22
Huang, L., Zeng, Y., Li, Y., Zhu, Y., He, Y., Liu, Y., Robert, A., & Meunier, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122691 · Cited by 19
“Unfortunately, despite tremendous efforts by universities and pharmaceutical companies to research it, very few new treatments have been approved since memantine in 2003 [1,2].”
BackgroundDiomede, L., Zanier, E. R., Moro, F., Vegliante, G., Colombo, L., Russo, L., Cagnotto, A., Natale, C., Xodo, F. M., Luigi, A. D., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02101-3 · Cited by 20
“In the last 15 years, various therapeutic approaches targeting pathological tau forms, mainly tau aggregation inhibitors and anti-tau monoclonal antibodies, have been developed and tested [10].”
BackgroundStanciu, G. D., Ababei, D. C., Solcan, C., Bild, V., Ciobîcă, A., Chiriac, S. I. B., Ciobanu, L., & Tamba, B.-I. (2023) · Pharmaceuticals · doi:10.3390/ph16111620 · Cited by 21
“Consequently, much of the therapeutics have focused on the extracellular deposits of the A β protein and intracellular accumulation of neurofibrillary tangles of the tau protein [2,6,7].”
BackgroundPenny, L. K., Lofthouse, R. A., Arastoo, M., Porter, A., Palliyil, S., Harrington, C. R., & Wischik, C. M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00417-w · Cited by 21
Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases
Wu, Y.-F., Ma, B., Liu, C. Y., Li, D., & Sui, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810187 · Cited by 25
“Early studies indicated a 0.4% success rate for the clinical trials of AD therapies [266].”
BackgroundInfluentialVirgili, J., Lebbadi, M., Tremblay, C., St‐Amour, I., Pierrisnard, C., Faucher-Genest, A., Émond, V., Julien, C., & Calon, F. (2018) · Synapse · doi:10.1002/syn.22025 · Cited by 24
“NeuN has been widely used to estimate neuronal cell loss in neurodegenerative diseases (Davoli et al., 2002; Lok et al., 2013).”
MethodCosta, M., Josselin, R., Silva, D. F., Cardoso, S. M., May, N. V., Chaves, S., & Santos, M. A. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111039 · Cited by 18
Păunescu, H., Dima, L., Ghiţă, I., Coman, L., Ifteni, P. I., Fulga, I., & Coman, O. A. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001120 · Cited by 20
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 27
“230,231 One of the inherent limitations of using rodent models in AD research is their inability to fully replicate the broader pathological and clinical characteristics observed in human AD.”
Li, X., Wang, L., Cykowski, M. D., He, T., Liu, T., Chakranarayan, J., Rivera, A. L., Zhao, H., Powell, S. Z.-E., Xia, W., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.030 · Cited by 20
Pound, P., & Ram, R. (2020) · BMJ Open Science · doi:10.1136/bmjos-2019-100041 · Cited by 25
QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
Malone, K., & Hancox, J. C. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620942416 · Cited by 26
Hassanzadeh, M., Hassanzadeh, F., Khodarahmi, G., Rostami, M., Azimi, F., Nadri, H., & Moghadam, F. H. (2021) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.323915 · Cited by 19
“The insufficient efficacy of the currently available treatments, small number of drug candidates in clinical trials, and high failure rate of AD clinical trials suggest there is an urgent need to further research in this area (8,9).”
BackgroundTung, M., Fung, K.-M., Hsu, H.-M., & Tseng, T. (2021) · RSC Advances · doi:10.1039/d1ra05311f · Cited by 20
Marianetti, M., Pinna, S., Venuti, A., & Liguri, G. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12278 · Cited by 24
“(2) Improving memory: All three indicators are significant at 1% level; Rey Auditory Verbal Learning Test–Immediate Recall, Rey Auditory Verbal Learning Test–Delayed Recall, and Rey Complex Figure–Immediate Recall show an improvement of 7%, 300%, and 92%, respectively, for treatment group, compared to a deterioration…”
BackgroundGinkgolides and Huperzine A for complementary treatment of Alzheimer's disease
Villegas, C., Perez, R., Petiz, L. L., Glaser, T., Ulrich, H., & Paz, C. (2022) · IUBMB Life · doi:10.1002/iub.2613 · Cited by 20
“In the past 20–30 years, attempts have been made to develop inhibitors capable of decreasing Aβ42 production, but unfortunately, these efforts did not produce inhibitors capable of moving beyond advanced stages of research.(14,15) However, at present, progress in establishing etiopathological factors of AD has led to…”
BackgroundThe Convergence of Alzheimer’s Disease Pathogenesis Concepts
Kozin, S. A., & Makarov, A. А. (2019) · Molecular Biology · doi:10.1134/s0026893319060104 · Cited by 19
Liu, X., Jiang, Y., Peng, W., Wang, M., Chen, X., Li, M., Ruan, Y., Sun, S., Yang, T., Yang, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.964886 · Cited by 25
Zhang, X., Ren, H., Pei, Z., Lian, C., Su, X., Lan, X., Chen, C., Lei, Y., Li, B., & Guo, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1066290 · Cited by 21
Acha, B., Corroza, J., de Gordoa, J. S., Cabello, C., Robles, M., Méndez-López, I., Macías, M., Zueco, S., Roldán, M., Urdánoz‐Casado, A., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207865 · Cited by 21
Jahnke, H., Krinke, D., Seidel, D., Lilienthal, K., Schmidt, S., Azendorf, R., Fischer, M., Mack, T. G. A., Striggow, F., Althaus, H., et al. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.07.074 · Cited by 19
Ropacki, M. T., Hannesdóttir, K., Hendrix, S. B., Gordon, M. F., Stephenson, D. T., Coons, S. J., & Stern, R. A. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016689712 · Cited by 18
“More than a decade has passed since the last new drug for Alzheimer disease (AD) obtained regulatory approval, though hundreds of compounds have entered clinical trials but failed to achieve their primary endpoint(s) during this time.(1) One possible explanation for these disappointing clinical trials is that successf…”
BackgroundMethodBagewadi, S., Raschka, T., Naz, M., Simoes, R. D. M., Senger, P., & Hofmann‐Apitius, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170011 · Cited by 24
“%) in Phase III trials have resulted in no new FDA approved drugs since 2003 [2].”
BackgroundLee, S., Kim, J. Y., Kim, E., Seo, K. Y., Kang, Y. J., Kim, J. Y., Kim, C. H., Song, H., Saksida, L. M., & Lee, J. E. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.4.277 · Cited by 21
Disease Modification in Alzheimer’s Disease: Current Thinking
Liu‐Seifert, H., Schumi, J., Miao, X., Tian, Y., Rabbia, M. A., Andersen, S. W., Wilson, S., Li, W., & Entsuah, R. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00068-4 · Cited by 18
Limbocker, R., Mannini, B., Cataldi, R., Chhangur, S., Wright, A. K., Kreiser, R. P., Albright, J. A., Chia, S., Habchi, J., Sormanni, P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124542 · Cited by 21
“Intense focus on inhibiting Aβ deposition has resulted in the characterization of numerous molecules, including small molecules, antibodies and molecular chaperones, which are able to prevent Aβ aggregation, and therefore, reduce the rate of Aβ oligomer formation, although no disease-modifying compound has yet been ap…”
BackgroundRaamana, P. R., Strother, S. C., & for the Australian Imaging Biomarkers, L. F. S. O. A. (2020) · Brain Structure and Function · doi:10.1007/s00429-020-02136-0 · Cited by 19
The search for Alzheimer disease therapeutics — same targets, better trials?
Rafii, M. S., & Aisen, P. S. S. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00414-3 · Cited by 19
An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?
Merighi, S., Poloni, T. E., Pelloni, L., Pasquini, S., Varani, K., Vincenzi, F., Borea, P. A., & Gessi, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652455 · Cited by 20
NMR Studies of Tau Protein in Tauopathies
Kitoka, K., Škrabana, R., Gašparik, N., Hritz, J., & Jaudzems, K. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.761227 · Cited by 17
Alzheimer’s Disease: Current Perspectives and Advances in Physiological Modeling
Boder, E. J., & Banerjee, I. A. (2021) · Bioengineering · doi:10.3390/bioengineering8120211 · Cited by 18
Cacabelos, R. (2018) · Future Neurology · doi:10.2217/fnl-2017-0038 · Cited by 18
Lysosomal Dysregulation in the Murine App Model of Alzheimer’s Disease
Whyte, L. S., Hassiotis, S., Hattersley, K. J., Hemsley, K. M., Hopwood, J. J., Lau, A. A., & Sargeant, T. J. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.042 · Cited by 22
(2018) · Nature Medicine · doi:10.1038/nm.4515 · Cited by 18
Chalatsa, I., Arvanitis, D. A., Mikropoulou, E. V., Giagini, A. T., Papadopoulou‐Daifoti, Z., Aligiannis, N., Halabalaki, M., Tsarbopoulos, A., Skaltsounis, A., & Sanoudou, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170862 · Cited by 19
“By 2050, more than 100 million people are expected to be affected worldwide [1].”
Femminella, G. D., Initiative, T. A. D. N., Taylor‐Davies, G., Scott, J., & Edison, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180365 · Cited by 23
“To date there is no drug effectively altering the progression of AD [3].”
Nanoparticle-based colorimetric sensors to detect neurodegenerative disease biomarkers
Fan, Q., Gao, Y., Mazur, F., & Chandrawati, R. (2021) · Biomaterials Science · doi:10.1039/d1bm01226f · Cited by 20
Integrating Transcriptomics, Genomics, and Imaging in Alzheimer's Disease: A Federated Model
Wu, J., Chen, Y., Wang, P., Caselli, R. J., Thompson, P. M., Wang, J., & Wang, Y. (2022) · Frontiers in Radiology · doi:10.3389/fradi.2021.777030 · Cited by 17
“Recent clinical trials targeting single molecular mechanisms have failed (11, 12).”
BackgroundPower, M. C., Engelman, B., Wei, J., & Glymour, M. M. (2022) · Epidemiologic Reviews · doi:10.1093/epirev/mxac002 · Cited by 18
Stem cells in the treatment of Alzheimer's disease – Promises and pitfalls
Bhatti, J. S., Khullar, N., Mishra, J., Kaur, S., Sehrawat, A., Sharma, E., Bhatti, G. K., Selman, A., & Reddy, P. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166712 · Cited by 22
Bi, Z., Wang, L., & Wang, W. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/161734 · Cited by 21
Bradshaw, A. C., Hughes, N., García, D. V., Chokoshvili, D., Owens, A. P., Hansen, C., Emmert, K., Maetzler, W., Killin, L. O. J., Barnes, R., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1187095 · Cited by 18
“, FDA approval of aducanumab in 2021, as the first diseasemodifying therapy for AD) (12), the failure rate in AD drug development remains very high (13, 14).”
BackgroundMulti-perspective neural network for dual drug repurposing in Alzheimer’s disease
Zhao, L., Li, Z., Chen, G., Yin, Y., & Chen, C. Y. (2023) · Knowledge-Based Systems · doi:10.1016/j.knosys.2023.111195 · Cited by 17
Designing drugs optimized for both blood–brain barrier permeation and intra-cerebral partition
Dichiara, M., Cosentino, G., Giordano, G., Pasquinucci, L., Marrazzo, A., Costanzo, G., & Amata, E. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2294118 · Cited by 15
The need for thorough phase II studies in medicines development for Alzheimer’s disease
Gray, J. A., Fleet, D., & Winblad, B. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0153-y · Cited by 17
“Introduction Not a single compound has successfully completed phase III in Alzheimer’s disease (AD) over the past 11 years [1, 2].”
BackgroundTezel, G., Timur, S. S., Bozkurt, İ., Türkoğlu, Ö. F., Eroğlu, İ., Nemutlu, E., Öner, L., & Eroğlu, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00511 · Cited by 20
Memory Support System training in mild cognitive impairment: Predictors of learning and adherence
Wit, L. D., Chandler, M. J., Amofa, P., DeFeis, B. L., Mejia, A., O’Shea, D. M., Locke, D. E. C., Fields, J. A., & Smith, G. E. (2019) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2019.1667833 · Cited by 23
Li, Y., Nguyen, M., Baudoin, M., Vendier, L., Liu, Y., Robert, A., & Meunier, B. (2019) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201900951 · Cited by 17
Lopes, J. P. B., da Silva, L. A. A., Ceschi, M. A., Lüdtke, D. S., Zimmer, A. R., Ruaro, T. C., Dantas, R. F., de Salles, C. M. C., Silva, F. P., Senger, M. R., et al. (2019) · MedChemComm · doi:10.1039/c9md00358d · Cited by 21
Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease
Wilkins, J. M., & Forester, B. P. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5262 · Cited by 17
Vasilopoulou, F., Bagán, A., Rodríguez‐Arévalo, S., Escolano, C., Griñán‐Ferré, C., & Pallàs, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050475 · Cited by 20
Rana, M., Pareek, A., Bhardwaj, S., Arya, G., Nimesh, S., Arya, H., Bhatt, T. K., Yaragorla, S., & Sharma, A. K. (2020) · RSC Advances · doi:10.1039/d0ra05172a · Cited by 17
Vasilopoulou, F., Griñán‐Ferré, C., Rodríguez‐Arévalo, S., Bagán, A., Abás, S., Escolano, C., & Pallàs, M. (2020) · GeroScience · doi:10.1007/s11357-020-00281-2 · Cited by 20
McEwen, S. C., Merrill, D. A., Bramen, J. E., Porter, V. R., Panos, S. E., Kaiser, S. A., Hodes, J. F., Ganapathi, A. S., Bell, L., Bookheimer, T., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12191 · Cited by 21
“At baseline and 12 months we collect: (1) FAST staging, (2) MESA 10-year Coronary Heart Disease Risk Score,37 (3) International Physical Activity Questionnaire (IPAQ),38 and (4) Food Frequency Questionnaire (FFQ).”
MethodKwon, Y. I. C., Xie, W., Zhu, H., Xie, J., Shinn, K., Juckel, N., Vince, R., More, S. S., & Lee, M. K. (2021) · Antioxidants · doi:10.3390/antiox10111796 · Cited by 18
“Despite significant effort, currently approved treatments for AD are symptomatic and do not impede the progression of the disease [3].”
Duarte-Abritta, B., Villarreal, M. F., Abulafia, C., Loewenstein, D., Curiel, R. E., Castro, M. N., Surace, E. I., Sánchez, S. M., Vigo, D. E., Vázquez, S., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.10.008 · Cited by 21
Ahnaou, A., Biermans, R., & Drinkenburg, W. H. I. M. (2018) · Neural Plasticity · doi:10.1155/2018/4270263 · Cited by 17
Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies
Rizzo, S. J. S., McTighe, S. M., & McKinzie, D. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_282 · Cited by 16
Traditional Chinese Medicine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Chen, Y., Zhang, D., Chen, T., Zhao, L., Wen, L., & Hou, R. H. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x25500016 · Cited by 16
Principles of Designing a Clinical Trial: Optimizing Chances of Trial Success
El-Hagrassy, M. M., Duarte, D. G. G., Thibaut, A., Lucena, M. F. G., & Fregni, F. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0152-y · Cited by 18
A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimer’s Disease
Chaudhury, S. S., Sannigrahi, A., Nandi, M., Mishra, V. K., De, P., Chattopadhyay, K., Mishra, S., Sil, J., & Mukhopadhyay, C. D. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1542-1 · Cited by 18
Lucero, E., Freund, R. K., Smith, A. N., Johnson, N. R., Dooling, B. R., Sullivan, E. J., Prikhodko, O., Ahmed, M. M., Bennett, D. A., Hohman, T. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105288 · Cited by 14
A review of therapeutic failures in late-stage clinical trials
Jain, R., Subramanian, J., & Rathore, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161366 · Cited by 25
“Till now, there are only five FDAapproved symptomatic treatment drugs in the market, and nothing to treat the disease itself [33].”
BackgroundGehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 20
Xu, J., Song, W., Xu, Z., Danziger, M. M., Karavani, E., Zang, C., Chen, X., Li, Y., Paz, I. R., Gohel, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14373 · Cited by 20
“Compared to DAM and tau microglia, upregulated DEGs in NIM were enriched with more immune pathways across all datasets and brain regionsinADorBraakstageVIsamples(Figures3,4,andFiguresS9A,C and S10A in supporting information).”
Self-citationInnovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease
Park, J. M., & Tsai, L. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003046 · Cited by 27
“Pharma-ceutical drugs that showed great promise in animal models have often failed to deliver results in human clinical trials [53,54].”
Łuczkowski, M. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.03.001 · Cited by 18
Rodríguez, M. H., Morales, L. G. F., Correa‐Basurto, J., & Rosales‐Hernández, M. C. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_9 · Cited by 17
Wu, X., Kosaraju, J., Zhou, W., & Tam, K. Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.003 · Cited by 16
Chan, M., Eacott, M. J., Sanderson, D. J., Wang, J., Sun, M., & Easton, A. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00214 · Cited by 18
Ion, D., Mihai, D. P., Lupașcu, G., & Nițulescu, G. M. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1526115 · Cited by 16
“…problem of finding a viable treatment for Alzheimer ’ s disease (AD) has been a major topic in the scientific world for many years now; yet little progress has been made in this direction (Cummings, Morstorf, & Zhong, 2014), taking into account the effort that has been invested in this endeavour.”
BackgroundClass-Specific Incidence of All-Cause Dementia and Alzheimer’s Disease: A Latent Class Approach
Zammit, A. R., Hall, C. B., Katz, M. J., Terrera, G. M., Ezzati, A., Bennett, D. A., & Lipton, R. B. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180604 · Cited by 16
Animal Research for Alzheimer Disease: Failures of Science and Ethics
Pippin, J. J., Cavanaugh, S. E., & Pistollato, F. (2019) · BRILL eBooks · doi:10.1163/9789004391192_021 · Cited by 16
Navigating the disease landscape: knowledge representations for contextualizing molecular signatures
Saqi, M. A. S., Lysenko, A., Guo, Y., Tsunoda, T., & Auffray, C. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby025 · Cited by 19
“[124, 125], with particular challenges for cardiovascular [126] and neurodegenerative diseases [127, 128], mean that increasingly more complex strategies for managing disease are needed to make progress [129].”
BackgroundSpatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD
Richter, N., Nellessen, N. D., Dronse, J., Dillen, K. N. H., Jacobs, H. I. L., Langen, K., Dietlein, M., Kracht, L., Neumaier, B., Fink, G. R., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101978 · Cited by 19
Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s disease patients
Lim, B., Tsolaki, M., Batruch, I., Anastasiou, A., Frontistis, A., Prassas, I., & Diamandis, E. P. (2019) · F1000Research · doi:10.12688/f1000research.21140.1 · Cited by 17
Wu, S., Zhang, J., Jiang, C., Wang, S., Que, R., & An, L. (2020) · Food & Function · doi:10.1039/d0fo00161a · Cited by 17
Konecny, J., Misiachna, A., Hrabinová, M., Pulkrabkova, L., Benková, M., Prchal, L., Kucera, T., Kobrlová, T., Finger, V., Kolcheva, M., et al. (2020) · Biomolecules · doi:10.3390/biom11010003 · Cited by 17
Lee, J., Lee, K., & Lim, C. T. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c04833 · Cited by 16
Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models
Gurdon, B., & Kaczorowski, C. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105558 · Cited by 17
Wang, Y., Huynh, T. T., Bandara, N., Cho, H., Rogers, B. E., & Mirica, L. M. (2021) · Dalton Transactions · doi:10.1039/d1dt02767k · Cited by 18
Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice
Beglopoulos, V., Tulloch, J., Roe, A. D., Daumas, S., Ferrington, L., Watson, R., Fan, Z., Hyman, B. T., Kelly, P. A. T., Bard, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11761 · Cited by 19
Nutrition as a component of dementia risk reduction strategies
Greenwood, C. E., & Parrott, M. D. (2016) · Healthcare Management Forum · doi:10.1177/0840470416662885 · Cited by 18
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
